Aeterna Zentaris taps Ergomed for Phase III study; FDA revamps REMS site;

> Aeterna Zentaris ($AEZS) picked CRO Ergomed to help run a Phase III trial of its macimorelin, designed to treat adult growth hormone deficiency. More

> The FDA has overhauled its Risk Evaluation and Mitigation Strategies (REMS) website to make it easier to find up-to-date information. News